|
US2015141356A1
|
|
Treatment of Clostridium Difficile Infection in High Risk Patients
|
|
AU2013254941A1
|
|
Compositions of stable tiacumicins
|
|
US2015157653A1
|
|
Prevention of Clostridium Difficile Infection in High Risk Patients
|
|
JP2012229264A
|
|
18-membered macrocyclic compound and analogous compound thereof
|
|
WO2012106722A2
|
|
Treatment of bacterial infections
|
|
WO2011146624A2
|
|
Methods of treating recurring bacterial infection
|
|
CA2799386A1
|
|
Treatment of clostridium difficile infection in patients undergoing antibiotic therapy
|
|
ZA200905337B
|
|
Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
|
|
US2008176927A1
|
|
Compositions of stable tiacumicins
|
|
US2007259949A1
|
|
Polymorphic crystalline forms of tiacumicin B
|
|
US2008269145A1
|
|
18-membered macrocycles and analogs thereof
|
|
US2007105791A1
|
|
Method of treating clostridium difficile-associated diarrhea
|
|
CA2546861A1
|
|
Treatment of a condition in a mammal with administration of compounds and methods of use thereof
|
|
WO2005044197A2
|
|
Synthesis of glycopeptides with superior pharmacokinetic properties
|
|
CA2540586A1
|
|
Treatment of a condition in a mammal with administration of aminosugar and uses thereof
|
|
KR20050053598A
|
|
Tiacumicin production
|
